GLP-1 and PCOS: What the Research Actually Shows
GLP-1 medication prescriptions in women with PCOS increased seven-fold between 2021 and 2025. Here is what the clinical evidence shows about why — and what these medications can and cannot do for PCOS.
PCOS affects approximately 6–10% of women of reproductive age. It is the most common endocrine disorder in this group — yet for decades, treatment options remained limited to oral contraceptives to manage symptoms, metformin for insulin resistance, and lifestyle advice that was often underspecified and hard to implement.
GLP-1 receptor agonists are changing that picture rapidly. Between 2021 and 2025, semaglutide and tirzepatide prescriptions in women with PCOS increased more than seven-fold, according to real-world data from Truveta. The question is whether the evidence supports this surge — or whether it is outrunning the science.
GLP-1 medications show meaningful benefits for PCOS in clinical research. They produce significant weight loss, improve insulin resistance, reduce androgen levels, and may support more regular ovulation. A 2025 meta-analysis found GLP-1 medications superior to both metformin and placebo for BMI reduction and insulin sensitivity in women with PCOS.
They are not FDA-approved specifically for PCOS — they are prescribed off-label — and they must be stopped before attempting conception. But the evidence for their use in PCOS is growing steadily and the biological rationale is strong.
The Insulin–Androgen Cycle at the Heart of PCOS
To understand why GLP-1 medications benefit PCOS, you have to understand the role insulin plays in the condition. Insulin resistance is not just a metabolic complication of PCOS — in most cases, it is a core driver of it.
Cells become resistant to insulin
For reasons that are partly genetic and partly environmental, cells in muscle, fat, and liver tissue stop responding normally to insulin. Glucose uptake becomes impaired.
Pancreas produces more insulin to compensate
To move glucose out of the bloodstream, the pancreas secretes more insulin. Fasting insulin levels rise. This is hyperinsulinaemia — and it is measurable with a blood test.
Elevated insulin stimulates ovarian androgen production
Ovarian theca cells have insulin receptors. When insulin levels are chronically elevated, these cells increase androgen production — particularly testosterone. This is the link between insulin resistance and the hormonal symptoms of PCOS.
Excess androgens disrupt follicle development
Elevated testosterone and other androgens interfere with the normal development of ovarian follicles. Follicles fail to mature and ovulate normally, instead remaining as small cysts on the ovary surface — the polycystic appearance on ultrasound.
Result: irregular periods, acne, excess hair, infertility
Disrupted ovulation produces irregular or absent menstrual cycles. Elevated androgens produce acne, hirsutism, and hair thinning. The metabolic effects include weight gain particularly in the abdominal area, further worsening insulin resistance.
This cycle is why interventions that reduce insulin resistance — weight loss, metformin, and now GLP-1 medications — produce improvements in hormonal as well as metabolic markers. Reducing insulin levels reduces the stimulus for ovarian androgen production. The hormonal improvement follows from the metabolic improvement.
What the Research Actually Shows
The evidence base for GLP-1 medications in PCOS has grown substantially since 2022. Here is what has been established, what is emerging, and what remains uncertain.
GLP-1 medications produce significant weight loss in women with PCOS — comparable to what is seen in the general population in large trials. A 2025 meta-analysis published in Scientific Reports, which reviewed randomised controlled trials through October 2024, found GLP-1 medications produced significantly greater BMI reduction than both placebo and metformin in women with PCOS.
This is particularly relevant because weight loss in PCOS is notoriously difficult to achieve through diet and exercise alone — insulin resistance impairs fat mobilisation and increases hunger signalling, creating a physiological resistance to weight loss that goes beyond willpower. GLP-1 medications bypass this resistance by acting directly on appetite-regulating brain circuits.
HOMA-IR — the standard measure of insulin resistance — improves significantly with GLP-1 medication use in women with PCOS. The 2025 Scientific Reports meta-analysis found GLP-1 medications superior to metformin for insulin sensitivity outcomes in women with PCOS, which is clinically significant given that metformin has been the first-line insulin-sensitising treatment for PCOS for decades.
The mechanism is both direct and indirect. GLP-1 receptor agonists improve insulin secretion quality (glucose-dependent, preventing excess), reduce glucagon, and slow gastric emptying to moderate post-meal glucose spikes. Weight loss then further reduces insulin resistance through reduced visceral adiposity.
Clinical studies show GLP-1 medications reduce free androgen index (FAI) and total testosterone levels in women with PCOS. The 2025 meta-analysis found significant reductions in FAI and improvements in SHBG (sex hormone-binding globulin, which binds and inactivates androgens) compared to placebo.
The effect appears to be mediated primarily through the insulin pathway — as insulin resistance improves and insulin levels fall, the ovarian stimulus for androgen production decreases. Some animal research additionally suggests direct anti-inflammatory effects of semaglutide on ovarian tissue through AMPK/SIRT1/NF-κB signalling, though direct ovarian effects in humans require further study before clinical conclusions can be drawn.
Several studies report improvements in menstrual regularity and ovulation frequency in women with PCOS taking GLP-1 medications, particularly liraglutide. A clinical trial published in 2022 found that liraglutide produced significantly greater improvements in menstrual frequency than metformin in women with PCOS.
These improvements are likely mediated through a combination of weight loss, reduced insulin resistance, and lower androgen levels — all of which reduce the hormonal disruption that prevents normal follicle maturation. Whether GLP-1 medications have direct effects on ovarian function independent of metabolic improvement remains an active area of research.
Women with PCOS have elevated cardiovascular risk compared to age-matched controls — higher triglycerides, lower HDL cholesterol, and elevated LDL are common. GLP-1 medications have demonstrated improvements in lipid profiles in the general population, and early PCOS-specific data shows similar effects, including reductions in triglycerides and total cholesterol.
This is clinically relevant because cardiovascular risk management is an important but often under-addressed aspect of PCOS care. GLP-1 medications may address metabolic, hormonal, and cardiovascular risks simultaneously rather than requiring separate interventions for each.
GLP-1 Medications vs Metformin for PCOS
Metformin has been the standard pharmacological treatment for PCOS-related insulin resistance for decades. How do GLP-1 medications compare?
| Outcome | GLP-1 medications | Metformin |
|---|---|---|
| Weight / BMI reduction | Significant — superior to metformin in meta-analysis | Modest — typically 1–3kg |
| Insulin resistance (HOMA-IR) | Significant improvement — superior to metformin | Moderate improvement |
| Androgen reduction | Significant FAI and testosterone reduction | Moderate reduction |
| Menstrual regularity | Improvements reported — liraglutide vs metformin trial | Moderate improvement |
| GI side effects | Nausea, vomiting common initially | Nausea, diarrhoea common initially |
| Route of administration | Injection (weekly) or oral (daily, Rybelsus) | Oral tablet daily |
| Cost | Higher — insurance coverage varies | Low — generic widely available |
| FDA approval for PCOS | Not approved — off-label use | Not approved — off-label use |
Neither metformin nor GLP-1 medications are FDA-approved specifically for PCOS. Both are used off-label. The growing evidence suggests GLP-1 medications produce greater metabolic and hormonal improvements — but at higher cost and with a different side effect profile. For women who cannot tolerate or afford GLP-1 medications, metformin remains a clinically valid first-line option.
What GLP-1 Medications Cannot Do for PCOS
The evidence is promising. But it is also important to be specific about what these medications do not do.
They do not cure PCOS. PCOS is a lifelong hormonal condition with genetic underpinnings. GLP-1 medications manage symptoms and metabolic markers while you take them. When discontinued, weight tends to return and hormonal markers tend to worsen back toward baseline, as seen in the general GLP-1 discontinuation literature.
They do not replace lifestyle intervention. The metabolic benefits of GLP-1 medications in PCOS are substantially amplified by appropriate nutrition and exercise. Women with PCOS who combine GLP-1 medication with structured protein intake and resistance training preserve more muscle mass, maintain more of their weight loss, and have better insulin sensitivity outcomes than those relying on medication alone.
They must be stopped before conception. GLP-1 medications are not safe during pregnancy — their effects on fetal development have not been adequately studied, and animal data raises concerns. Current guidance from most endocrinological societies recommends stopping GLP-1 medications at least two months before attempting conception, to allow the drug to clear before pregnancy begins.
The evidence base is still growing. Most PCOS-specific GLP-1 trials to date have been relatively small and short-term. Long-term data on outcomes including fertility, cardiovascular risk, and endometrial health in women with PCOS on GLP-1 medications is still accumulating. As of 2025, there are 13 registered clinical trials specifically examining GLP-1 medications in PCOS.
The fertility question — what to discuss with your doctor
Women with PCOS who are trying to conceive face a specific clinical question: GLP-1 medications may improve ovulation regularity and reduce androgen levels, which could theoretically improve fertility. But they must be stopped before attempting conception.
The practical approach most reproductive endocrinologists currently recommend: use GLP-1 medications to achieve weight loss and metabolic improvement, then transition off the medication under medical supervision before attempting conception. The improved metabolic baseline — lower insulin resistance, reduced androgen levels, potentially more regular cycles — may then support better fertility outcomes than the pre-treatment state.
This is an active clinical conversation. Any decision about GLP-1 medications and fertility should involve a reproductive endocrinologist or OB-GYN, not just a GP. See Ozempic and Pregnancy: What You Need to Know for the full stopping guidance.
Nutrition for PCOS on GLP-1 Medications
Women with PCOS on GLP-1 medications have the same core nutritional priorities as all GLP-1 users — but with some PCOS-specific considerations that change the emphasis.
Protein first — 0.7–1.0g per pound
Protein protects muscle mass during the rapid weight loss GLP-1 medications produce. In PCOS, preserving muscle mass is particularly important because muscle tissue is the primary site of insulin-mediated glucose uptake — more muscle means better insulin sensitivity. Target 0.7–1.0g per pound of body weight daily using the GLP-1 Protein Calculator.
Low-glycaemic carbohydrates
Women with PCOS are more sensitive to carbohydrate-driven insulin spikes than the general population. Replacing refined carbohydrates with low-glycaemic alternatives — legumes, oats, sweet potatoes, whole grains — reduces post-meal insulin response and complements the GLP-1 medication’s glucose-moderating effect. This is not a low-carb diet prescription — it is a carbohydrate quality priority.
Anti-inflammatory foods
PCOS has a significant inflammatory component — elevated inflammatory markers are common and contribute to insulin resistance. Omega-3 rich foods (fatty fish, walnuts, flaxseed), extra virgin olive oil, colourful vegetables, and berries all have anti-inflammatory properties relevant to PCOS. These foods also support natural GLP-1 production from L-cells through FFAR1 and FFAR4 receptor activation.
Fermentable fibre for gut and hormone health
Gut microbiome composition is disrupted in many women with PCOS compared to controls. Fermentable dietary fibre from legumes, oats, chia seeds, and vegetables feeds beneficial gut bacteria, supports SCFA production that stimulates natural GLP-1 release, and helps regulate oestrogen metabolism through the enterohepatic circulation. Targeting 25–35g of fibre per day is appropriate for most women with PCOS.
Resistance training is particularly important for women with PCOS on GLP-1 medications. Muscle tissue is the primary site of insulin-mediated glucose uptake — building and maintaining muscle directly improves insulin sensitivity, the central metabolic problem in PCOS. Two to three resistance training sessions per week, combined with adequate protein intake, protects lean mass during weight loss and amplifies the insulin-sensitising benefit of the medication. See Best Exercise to Boost Metabolism for the full protocol.
Frequently Asked Questions
Yes — GLP-1 receptor agonists show meaningful clinical benefits for PCOS. They produce significant weight loss, improve insulin resistance, reduce androgen levels, and may support more regular ovulation. A 2025 meta-analysis found GLP-1 medications superior to both metformin and placebo for BMI reduction and insulin sensitivity in women with PCOS. They are not FDA-approved specifically for PCOS but are increasingly prescribed off-label for this indication.
Insulin resistance is central to PCOS pathology, not just a side effect. When cells resist insulin, the pancreas produces more to compensate. Elevated insulin levels then stimulate ovarian theca cells to produce excess androgens, particularly testosterone. This disrupts normal follicle development, prevents ovulation, and produces the characteristic hormonal symptoms of PCOS — irregular periods, acne, and hirsutism. Breaking this insulin-androgen cycle through insulin-sensitising treatments produces hormonal improvements alongside metabolic ones.
No head-to-head trial has compared semaglutide and tirzepatide specifically in women with PCOS. Based on general weight loss data, tirzepatide produces greater average weight loss (approximately 22% vs 15%), which may translate to greater PCOS symptom improvement. However, individual response, tolerability, insurance coverage, and specific health history should determine the choice — a decision to make with a healthcare provider, not based on averages alone.
GLP-1 medications may improve fertility markers indirectly — by reducing insulin resistance, lowering androgen levels, and restoring more regular ovulation through weight loss. However, they must be stopped at least two months before attempting conception due to unknown fetal safety. The typical clinical approach is to use GLP-1 medications to achieve metabolic improvement, then transition off before trying to conceive. Any fertility decisions should involve a reproductive endocrinologist.
Yes — clinical studies show GLP-1 medications reduce free androgen index (FAI) and total testosterone in women with PCOS, and improve SHBG levels. This effect is primarily mediated through improved insulin sensitivity — as insulin levels fall, the ovarian stimulus for androgen production decreases. Animal research also suggests possible direct anti-inflammatory effects on ovarian tissue, though human evidence for direct ovarian effects requires further study.
Protein is the priority — 0.7–1.0g per pound of body weight daily protects muscle mass and directly improves insulin sensitivity. Low-glycaemic carbohydrates are preferable to refined carbohydrates to minimise insulin spikes. Anti-inflammatory foods including fatty fish, olive oil, and vegetables address the inflammatory component of PCOS. Fermentable fibre from legumes, oats, and chia seeds supports gut health and natural GLP-1 production. Aim for 25–35g of fibre daily.
Research & References
- Truveta Research. Rising use of GLP-1 medications among women with PCOS. Truveta. December 2025.
- Chen X, et al. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Scientific Reports. 2025;15:14822.
- Morais BAA, et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis. Journal of Diabetes and Its Complications. 2024;38(10):108834.
- Ding H, et al. Resistance to insulin and elevated level of androgen: a major cause of polycystic ovary syndrome. Frontiers in Endocrinology. 2021;12:741764.
- Bednarz K, et al. The role of GLP-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. International Journal of Molecular Sciences. 2022;23(8):4334.
- Liu M, et al. Semaglutide alleviates ovary inflammation via the AMPK/SIRT1/NF-κB signalling pathway in polycystic ovary syndrome mice. Drug Design, Development and Therapy. 2024;18:3925–3938.
- Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: what’s new? Advances in Clinical and Experimental Medicine. 2017;26(2):359–367.
- Xing C, et al. Insulin sensitizers for improving the endocrine and metabolic profile in overweight women with PCOS. Journal of Clinical Endocrinology & Metabolism. 2020;105(9):2950–2963.